Navigation Links
Drug slows prostate tumor growth by keeping vitamin A active
Date:11/6/2007

SINGAPORE -- A novel compound that blocks the breakdown of retinoic acid, derived from vitamin A, is a surprisingly effective and promiscuous agent in treating animal models of human prostate cancer, say investigators from the University of Maryland, Baltimore (UMB).

Daily injections of the agent VN/14-1 resulted in up to a 50 percent decrease in tumor volume in mice implanted with human prostate cancer cells, reported Aakanksha Khandelwal, Ph.D., today at the American Association for Cancer Research Centennial Conference on Translational Cancer Medicine. No further tumor growth was seen during the five-week study, Khandelwal reports.

Importantly, VN/14-1 exerted its effects in multiple ways, which is the hallmark of a so-called promiscuous drug, according to the studys senior investigator, Vincent C.O. Njar, Ph.D., associate professor in the Department of Pharmacology and Experimental Therapeutics within UMBs School of Medicine.

This potent agent causes cancer cells to differentiate, forcing them to turn back to a non-cancerous state − which is what we expected it would do − but it also stops cancer growth by arresting the cell cycle and pushes cells to die by inducing programmed cell death, Njar said.

These functions were unexpected and wonderfully surprising, he said. I am not aware that any other drug currently used to treat prostate cancer targets so many pathways.

Vitamin A, when converted by the body into retinoic acid, is known to be involved in maintaining the normal growth of cells, and other research has shown that prostate cancer cells contain five to eight times less retinoic acid than normal prostate cells. Njars laboratory developed a number of compounds, including VN/14-1, with the aim of inhibiting the normal breakdown of retinoic acid in cancer cells.

The agent is similar in function to the well-known acne and anti-aging therapy, Retin-A, as well as to the leukemia drug Vesanoid. These products, known as retinoids, add all-trans retinoic acid (ATRA) to skin or cancer cells. VN/14-1, which is a retinoic acid metabolism blocking agent (RAMBA), works by inhibiting the breakdown of ATRA, keeping more retinoic acid available within cancer cells so that the chemical can redirect these cells back into their normal growth patterns, which includes programmed cell death.

Our idea is that rather than give extra ATRA, we would prevent ATRA already available within cells from being broken down, Njar said. We now call VN/14-1 an atypical RAMBA because in addition to blocking ATRA metabolism, it has other multiple desirable anti-cancer effects.

VN/14-1 works by blocking the CYP26 enzyme that actually transforms ATRA into inactive compounds, he says. The researchers have successfully tested VN/14-1 in breast cancer cells and have been funded to study the compound in preclinical studies that can lead to a Phase I human clinical trial.

In this study, the researchers found in mouse models of human prostate cancer that a 5 mg/kg (milligram per kilogram) dose injected daily resulted in a 33 percent reduction in tumor size; a dose twice as large reduced tumors by 50 percent.

They also tested a dose of 20 mg/kg through oral and intravenous administration to study the concentration of VN/14-1 in the blood over time in rats. They found that the amount of VN/14-1 in the blood after oral administration was exceptionally high compared to intravenous VN/14-1. This indicates that VN/14-1 should be tested orally as this is the preferred route of drug administration in humans, Njar says. Giving an agent orally in small doses is exactly what you want in an anti-cancer drug, he said.


'/>"/>
Contact: Staci Vernick Goldberg
staci.goldberg@aacr.org
267-646-0616
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Health Insurance Premium Growth Slows for Fourth Straight Year
2. Philanthropic Giving for Health Care Slows in 2006 in both U.S. and Canada, According to Association for Healthcare Philanthropys Annual Report on Giving
3. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
4. First biomarker discovered that predicts prostate cancer outcome
5. Frequent Prostate Screens Fail to Improve Aggressive Cancer Diagnoses
6. New male sling procedure helps prostate cancer survivors who suffer from urinary incontinence
7. Us TOO Launches National SEA Blue Campaign for Prostate Cancer Awareness Month
8. Red wine compound shown to prevent prostate cancer
9. Barbershop Talks Cut Black Mens Prostate Cancer Risk
10. Generic prostate drug helps find high-risk cancers early
11. Finasteride unlikely to induce high grade prostate cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... Calif. (PRWEB) , ... April 29, 2016 , ... Our ... An effective way to confront and deal with these stressors is to adopt a ... to be good for you. Risa Groux, a certified Holistic Nutritionist and the creator ...
(Date:4/29/2016)... ... ... On Tuesday, April 26, 2016 members of the HomeTown Health network, a ... Deal on SB 258, the “Rural Health Care Relief” Bill. , The bill, which ... to individuals and corporations which donate directly to a “rural hospital” in Georgia, and ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... of our nation’s productivity, stability, even security. Most importantly, employees are the single ... Then why are American workers so unhappy? , Just under half of American ...
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. Bernie Siegel, ... "LOVE, MEDICINE and MIRACLES") addresses touchy topics related to Death live on ... Dr. Bernie Siegel, author of a plethora of essential books-to-read for physicians ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... more flexibility in repaying their loans, more information about their loan terms and ... total outstanding student loan debt, including federal and private loans, has reached $1.3 ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... 29, 2016  In the next ten years, ... from systems dependent on CRTs monitors to those reliant ... CRT Medical monitors and will automatically sync to ... of foreseeable benefits to this technological advancement, it ... have to be replaced in order to be ...
(Date:4/29/2016)... ReportsnReports.com adds "Pulmonary Arterial ... report that provides an overview of the PAH ... stages, therapeutics assessment by drug target, mechanism of ... type, along with latest updates, and featured news ... involved in the therapeutic development for Pulmonary Arterial ...
(Date:4/29/2016)... 2016 Acquisition Expands the ... Development Capabilities in North America ... Indegene ( http://www.indegene.com ), a ... of Skura Corporation,s life science business. Skura,s SFX ... enablement technology for life science organizations and delivers ...
Breaking Medicine Technology: